Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis With Lanadelumab in Hereditary Angioedema: Prospective, Phase 4, Noninterventional EMPOWER Real-World Study
media
posted on 2025-05-15, 10:42 authored by Adis journals on behalf of, Jonathan A. Bernstein, Stephen D. Betschel, Paula J. Busse, Aleena Banerji, H. James Wedner, Michael Manning, Rafael H. Zaragoza-Urdaz, John Anderson, Remi Gagnon, Alan P. Baptist, Daniel Soteres, William R. Lumry, Timothy Craig, Daniel Petroni, F. Ida Hsu, Daniel Nova Estepan, Salomé Juethner, Maureen Watt, Natalie Khutoryansky, Bruce L. ZurawThe article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days.
The above graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online (see “read the peer-reviewed publication” opposite).
